Innovative product line is purpose-built to streamline the manufacture of allogeneic cell therapies. Available exclusively from Teknova starting today. HOLLISTER, Calif., March 19, 2025 – Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx’s PluriFreezeTM cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical […]

Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx’s Novel PluriFreezeTM Cryopreservation System HOLLISTER, Calif., March 11, 2025 – Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by

Seattle, WA – Pluristyx, the leading provider of innovative induced pluripotent stem cells (iPSC), announces the issuance of the groundbreaking induced Allogeneic Cell Tolerance (iACT Stealth™) U.S. Patent No. 12,178,835. This patent marks a significant milestone in Pluristyx's mission to bring advanced cell therapy solutions to the global market. Additionally, patents for iACT Stealth™ have been

Streamlined regulatory documentation accelerates development of next generation therapies Seattle, WA – Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its PluriBank™ CG (Clinical Grade) iPSC lines.  This comprehensive regulatory submission details

DURHAM, N.C. and SEATTLE, W.A., January 28, 2025 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, and Pluristyx, Inc. today announced an expanded partnership. Pluristyx makes and sells PluriBank™ iPSC lines as part of their tools, technologies, and services to support the development of

SEATTLE, WA January 7, 2025 -- Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate availability of the PSXi013 iPSC line made under GMP. This off-the-shelf, readily available cell line will revolutionize the cell and gene therapy landscape, breaking the mold of how cells

SEATTLE, W.A., July 9, 2024 -- Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale.  Humacyte has licensed Pluristyx’s clinical-grade PluriBank™ induced Pluripotent Stem Cell